ClinicalTrials.gg
Not yet recruitingNCT07514507MelOptUpdated Apr 7, 2026

Optimization of Melatonin Administration in Healthy Adults

An interventional study of Mel 2 mg 30 min and Mel 2 mg 3 h in Sleep Disorders, sponsored by IRCCS Fondazione Stella Maris. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by IRCCS Fondazione Stella Maris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Sleep Wake Disorders with a site in Italy — 14 open to participants now, 18 under way, 4 of them phase 3. Sleep Wake Disorders · Italy.

Planned enrollment
15th of 15
14 · median 57
Started
2026
with 3 others
No phase
7 of 29
2 open now
Primary completion
2026-08
later than 11 of 17 live
Registered
24th of 29
by date
Lead sponsor
1 of 29
IRCCS Fondazione Stella Maris

Among the 29 studies in Sleep Wake Disorders with a site in Italy, this one is the 15th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 24th registered.

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 181 are open to participants now.

Browse Sleep Wake Disorders studies →

Open to participants now

14 of the 29 studies in Sleep Wake Disorders with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 114 Sleep Wake Disorders studies recruiting now, 40 (35%) set no upper age limit and 53 (46%) stop at 75 or younger; 22 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Sleep Wake Disorders with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether the timing and dosage of exogenous melatonin can improve sleep onset and maintenance in healthy adults aged 18-45 years (50% female) with no history of sleep disorders.

The main questions it aims to answer is whether an optimized melatonin administration schedule (4 mg, 3 hours before bedtime) will be more effective in improving sleep initiation and maintenance than an administration schedule more commonly advised (2 mg, 30 minutes before bedtime).

Researchers will compare five conditions involving different combinations of melatonin or placebo administered 30 minutes or 3 hours before bedtime to see if earlier timing and/or higher dosage produces better sleep outcomes.

Participants will:

  • Complete a habituation night without any intervention.
  • Undergo five randomized, double-blind experimental sleep conditions including:

    2 mg melatonin 30 minutes before bedtime 2 mg melatonin 3 hours before bedtime 4 mg melatonin 30 minutes before bedtime 4 mg melatonin 3 hours before bedtime Placebo at both time points

  • Be monitored via polysomnography to measure sleep parameters
03

Conditions studied

  • Sleep Disorders

Browse trials for

Keywords

  • melatonin
  • sleep health
  • sleep drugs
  • hypnotics and sedatives
  • drug administration schedule
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 45 years of age
  • Fluent knowledge of Italian language
  • Review and signing of the form

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of sleep or circadian rhythm disorder
  • Diagnosis of neurological, psychiatric or medical condition that may interfere with sleep
  • Ongoing treatment with medications that may affect sleep, including hypnotics and other types of melatonin
  • Travel to a country with a time zone difference of at least two hours within the two months prior to or during the study
  • Shift work
  • Confirmed pregnancy
  • Breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
14 participants (estimated)

Study arms

  • Active comparator
    2mg 30min

    Dietary Supplement: Mel 2 mg 30 min

  • Experimental
    2mg 3h

    Dietary Supplement: Mel 2 mg 3 h

  • Experimental
    4mg 30min

    Dietary Supplement: Mel 4 mg 30 min

  • Experimental
    4mg 3h

    Dietary Supplement: Mel 4 mg 3 h

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Dietary supplementHoneyStudies of HoneyHoney pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Melatonin 2 mg 30 minutes before bedtime, placebo 3 hours before bedtime

  • Dietary supplementHoneyStudies of HoneyHoney pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Placebo administered 30 minutes before bedtime, melatonin 2 mg administered 3 hours before bedtime

  • Dietary supplementHoneyStudies of HoneyHoney pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Melatonin 4 mg administered 30 minutes before bedtime, placebo administered 3 hours before bedtime

  • Dietary supplementHoneyStudies of HoneyHoney pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Placebo administered 30 minutes before bedtime, melatonin 4 mg administered 3 hours before bedtime

  • OtherPlacebo

    Placebo administered 30 minutes before bedtime, placebo administered 3 hours before bedtime

06

What researchers measure

Primary outcomes

  1. Sleep Onset Latency

    Time required to fall asleep assessed using polisomnography

    Time frame: First night following administration of the drug

Secondary outcomes

  1. Total Sleep Time

    Night sleep duration assessed using polisomnography

    Time frame: First night following administration of the drug

  2. Sleep Efficiency

    Ratio between total sleep time and time in bed

    Time frame: First night following administration of the drug

  3. Wake After Sleep Onset

    Minutes spent awake between the sleep onset and morning awakening

    Time frame: First night following administration of the drug

07

Study locations

1 site
  • University of Pisa, Institute of Physiology, Sonnolab
    Pisa, PI 56126, Italy
08

References and documents

Publications

  • Bruno S, Cenerini G, Lo Giudice L, Cruz-Sanabria F, Benedetti D, Crippa A, Fiori S, Ferri R, Masi G, Faraguna U. Optimizing timing and dose of exogenous melatonin administration in neuropsychiatric pediatric populations: a meta-analysis on sleep outcomes. Sleep Med Rev. 2025 Dec;84:102158. doi: 10.1016/j.smrv.2025.102158. Epub 2025 Aug 30. PubMed 40914024 ↗
  • Cruz-Sanabria F, Bruno S, Crippa A, Frumento P, Scarselli M, Skene DJ, Faraguna U. Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis. J Pineal Res. 2024 Aug;76(5):e12985. doi: 10.1111/jpi.12985. PubMed 38888087 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The data cannot be shared publicly for the privacy of individuals who participated in the study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.

Of 214 non-industry interventional studies with no phase under Sleep Wake Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's planned 3 months is below that.

Counting every sponsor, half of 249 studies reached it within 19 months; a quarter within 6 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Apr 7, 2026
StartEst.
May 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514507
Lead sponsor
IRCCS Fondazione Stella Maris
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
May 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Apr 7, 2026

Study contacts

Ugo Faraguna, MD, PhD
Contact
ugo.faraguna@unipi.it
+39 050 2213470

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Honey

Start the discussion